Protein Disulfide Isomerase
P4HBproteinPDI catalyzes disulfide bond formation in platelet integrins and coagulation factors, promoting thrombosis.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleRegulates platelet integrin activation and thrombosis; modulates inflammation.
Also acts inVascular inflammation, Coagulation / thrombus
Druggability
DruggableYes
Known drugs / candidates4
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000185624
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I75
C — confounder / Type-II67
A — assay feasibility72
E — evidence strength30
T1DI (composite)12
Specificity differential (R−C)+8.3
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.Proteomics · 2009 · PMID 19294693 · doi